Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents

Current Pharmaceutical Design

Volumn 10, Issue 29, 2004, Pages 3651-3662

  Green, Brian D ^a   Gault, Victor A ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GIP analogues; GLP 1 analogues; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic polypeptide (GIP); Type 2 diabetes

Indexed keywords

CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE DERIVATIVE; GLUCOSE; INSULIN; MICROSPHERE; PEPTIDE HYDROLASE INHIBITOR; PIOGLITAZONE; POLYMER; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; CELL FUNCTION; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; ENZYME ACTIVE SITE; ENZYME DEGRADATION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT CONCENTRATION; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 6344241190     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043382774     Document Type: Review

References (123)

1. Unger RH, Eisentraut AM. Entero-insular axis. Arch Intern Med 1969; 123: 261-266.
2. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
3. Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-I promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999; 42: 856-864.
4. Zhou J, Wang X, Pineyro MA, Egan JM. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 1999; 48: 2358-2366.
5. Trumper A, Trumper K, Trusheim H, Arnold R, Goke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001; 15: 1559-1570.
6. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003; 52: 741-750.
7. Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc Natl Acad Sci USA 1982; 79: 345-349.
8. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF. Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 1983; 80: 5485-5489.
9. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718.
10. Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF. Preproglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. Endocrinology 1984; 115: 2176-2181.
11. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-371.
12. Bailey CJ, Flatt PR. Glucagon-like peptide-1 and the entero-insular axis in obese hyperglycaemic (ob/ob) mice. Life Sci 1987; 40: 521-525.
13. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174.
14. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
15. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304.
16. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, et al. Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 1989; 38: 902-905.
17. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338-342.
18. Hendrick GK, Gjinovci A, Baxter LA, Mojsov S, Wollheim CB, Habener JF, et al. Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats. Metabolism 1993; 42: 1-6.
19. Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ. Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes 1998; 47: 632-639.
20. O'Harte FPM, Mooney MH, Lawlor A, Flatt PR. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000; 1474: 13-22.
21. O'Harte FPM, Mooney MH, Kelly CMN, Flatt PR. Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol 2000; 165: 639-648.
22. O'Harte FPM, Mooney MH, Kelly CM, McKillop AM, Flatt PR. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Regul Pept 2001; 96: 95-104.
23. Gutniak M, Ørskov C, Holst JJ, Ahren B, Ffendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1316-1322.
24. Eissele R, Koop H, Arnold R. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand J Gastroenterol 1990; 25: 449-454.
25. Creutzfeldt WO, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19: 580-586.
26. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 1987; 84: 3434-3438.
27. Fehmann HC, Habener JF. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 1992; 130: 159-166.
28. Skoglund G, Hussain MA, Holz GG. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 2000; 49: 1156-1164.
29. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000; 141: 4600-4605.
30. Edvell A, Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology 1999; 140: 778-783.
31. Hui H, Wright C, Perfetti R. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
32. De La Tour D, Halvorsen T, Demeterco C, Tyrberg B, Itkin-Ansari P, Loy M, et al. Beta-cell differentiation from a human pancreatic cell line in vitro and in vivo. Mol Endocrinol 2001; 15: 476-483.
33. Valverde I, Morales M, Clemente F, Lopez-Delgado MI, Delgado E, Perea A, et al. Glucagon-like peptide I: a potent glycogenic hormone. FEBS Lett 1994; 349: 313-316.
34. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 1994; 37: 1163-1166.
35. O'Harte FPM, Gray AM, Abdel-Wahab YHA, Flatt PR. Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscle. Peptides 1997; 18: 1327-1333.
36. Kosaka T, Lim RK. Demonstration of the humoral agent in fat inhibition of gastric secretion. Proc Soc Exptl Biol 1930; 27: 890-891.
37. Brown JC, Pederson RA, Jorpes E, Mutt V. Preparation of highly active enterogastrone. Can J Physiol Pharmacol 1969; 47: 113-114.
38. Brown JC, Pederson RA. Cleavage of a gastric inhibitory polypeptide with cyanogen bromide and the physiological action of the C-terminal fragment. J Physiol 1970; 210: 52P-53P.
39. Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57-64.
40. Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R. Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest 1978; 62: 152-161.
41. Dupre J, Ross SA, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828.
42. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 1976; 99: 780-785.
43. Pederson RA. In: Walsh JH, Dockray GJ Ed. Gut Peptides: Biochemistry and Physiology. New York, Raven Press 1994; 217-259.
44. Fehmann HC, Göke R. Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription. Peptides 1995; 16: 1149-1152.
45. Wang Y, Montrose-Rafizadeh C, Adams L, Raygada M, Nadiv O, Egan JM. GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells. Mol Cell Endocrinol 1996; 116: 81-87.
46. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 2002; 174: 233-246.
47. Elahi D, Meneilly GS, Minaker KL, Rowe JW, Andersen DK. Regulation of hepatic glucose production by gastric inhibitory polypeptide in man. Can J Physiol Pharmacol 1986; 65: A18.
48. O'Harte FPM, Abdel-Wahab YHA, Conlon JM, Flatt PR. Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells. Biochim Biophys Acta 1998; 1425: 319-327.
49. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007.
50. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979; 28: 1141-1142.
51. Oben J, Morgan LM, Fletcher J, Marks V. Effect of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991; 130: 267-272.
52. Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat adipose tissue. J Nutr 1995; 125: 183-188.
53. Gault VA, Flatt PR, O'Harte FPM. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003; 308: 207-213.
54. Gault VA, O'Harte FPM, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003; 37: 253-263.
55. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Charles MA, Bennett PH. A two-step model for development of non-insulin-dependent diabetes. Am J Med 1991; 90: 229-235.
56. Kahn SE, Porte DJ. In: Rifkin H, Porte DJ Eds, Diabetes Mellitus: Theory and Practice. New York, Elsevier 1990; 436-456.
57. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care 1990; 13: 992-1010.
58. Flatt PR. In: Flatt PR Ed. Nutrient regulation of insulin secretion. London, Portland Press Ltd. 1992
59. Göke R, Wagner B, Fehmann HC, Göke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 1993; 193: 97-103.
60. Jones IR, Owens DR, Luzio SD, Hayes TM. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus. Horm Metab Res 1989; 21: 23-26.
61. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
62. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 1995; 32: 13-16.
63. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
64. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404: 239-245.
65. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-1331.
66. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50: 1588-1597.
67. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 2002; 172: 355-362.
68. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, et al. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. Metabolism 1999; 48: 385-389.
69. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47: 1253-1258.
70. Burkey BF, Li X, Bolognese L, Russell M, Wang PR, Villhauer EB, Hughes TE. Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes 2002; 51(S2): A1383.
71. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, et al. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469.
72. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002; 51: 943-950.
73. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. Diabetes 2002; 51: 2677-2683.
74. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P.A, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
75. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
76. Holst JJ. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. Adv Exp Med Biol 2003; 524: 263-279.
77. 7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004; 180: 379-388.
78. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 1999; 48: 758-765.
79. Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, et al. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003; 31: 529-540.
80. 9-substituted analogues of glucagon-like peptide-1. Biol Chem 2003; 384: 1541-1551.
81. 9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39). Metabolism 2004; 53: 252-259.
82. 2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J Endocrinol 2003; 176: 133-141.
83. 2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism 2003; 52: 679-687.
84. Gault VA, O'Harte FPM, Harriott P, Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 2002; 290: 1420-1426.
85. 3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003; 46: 222-230.
86. 7 is crucial for GLP-1 action. Endocr J 1997; 44: 701-705.
87. Gallwitz B, Ropeter T, Morys-Wortmann C, Mentlein R, Siegel EG, Schmidt WE. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro. Regul Pept 2000; 86: 103-111.
88. 1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J 2002; 367: 913-920.
89. O'Harte FPM Gault VA, Parker JC, Harriott P, Mooney MH, Bailey CJ, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002; 45: 1281-1291.
90. Burcelin R, Dolci W, Thorens B. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1. Metabolism 1999; 48: 252-258.
91. Ritzel U, Leonhardt U, Ottleben M, Ruhmann A, Eckart K, Spiess J, et al. A synthetic glucagon-like peptide-1 analog with improved plasma stability. J Endocrinol 1998; 159: 93-102.
92. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998; 41: 271-278.
93. Siegel EG, Gallwitz B, Scharf G, Mentlein R, Morys-Wortmann C, Folsch UR, et al. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept 1999; 79: 93-102.
94. Siegel EG, Scharf G, Gallwitz B, Mentlein R, Morys-Wortmann C, Folsch UR, et al. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets. Eur J Clin Invest 1999; 29: 610-614.
95. Doyle ME, Greig NH, Holloway HW, Betkey JA, Bernier M, Egan JM. Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent. Endocrinology 2001; 142: 4462-4468.
96. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002; 51: 656-661.
97. Xiao Q, Giguere J, Parisien M, Jeng W, St Pierre SA, Brubaker PL, Wheeler MB. Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo. Biochemistry 2001; 40: 2860-2869.
98. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
99. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983; 32: 433-435.
100. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol (Copenh) 1986; 112: 224-229.
101. Ruiz-Grande C, Pintado J, Alarcon C, Castilla C, Valverde I, Lopez-Novoa JM. Renal catabolism of human glucagon-like peptides 1 and 2. Can J Physiol Pharmacol 1990; 68: 1568-1573.
102. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 2003; 10: 2471-2483.
103. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E754-E752.
104. Chou JZ, Place GD, Waters DG, Kirkwood JA, Bowsher RR. A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics. J Pharm Sci 1997; 86: 768-773.
105. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52: 751-759.
106. 8-substituted GLP-1 analogues. Biol Chem 2004; 385: 169-177.
107. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 1996; 19: 843-848.
108. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahren B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 1997; 20: 1874-1879.
109. Joseph JW, Kalitsky J, St-Pierre S, Brubaker PL. Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalizes basal glycaemia in diabetic db/db mice. Diabetologia 2000; 43: 1319-1328.
110. Burcelin R, Rolland E, Dolci W, Germain S, Carrel V, Thorens B. Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus. Ann NY Acad Sci 1999; 875: 277-285.
111. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000; 275: 34471-34477.
112. Critchley H, Davis SS, Farraj NF, Illum L. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol 1994; 46: 651-656.
113. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev 1998; 29: 185-194.
114. Choi WS, Murthy GG, Edwards DA, Langer R, Klibanov AM. Inhalation delivery of proteins from ethanol suspensions. Proc Natl Acad Sci USA 2001; 98: 11103-11107.
115. MacDonald PE, El-kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002; 51: S434-S442.
116. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-14847.
117. Knudsen LB, Agerso H, Huusfeldt PO, Nielsen PF, Wilken M. Derivatives of glucagon-like peptide-1 suitable for once daily administration. Diabetes 1999; 48(S1): A202.
118. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
119. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 2002; 451: 217-225.
120. Naslund E, Skogar S, Efendic S, Hellstrom PM. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept 2002; 106: 89-95.
121. Larsen PJ, Vrang N, Tang-Christensen M. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Curr Pharm Design 2003; 9(17): 1373-82.
122. Somsak L, Nagya V, Hadady Z, Docsa T, Gergely P. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments. Curr Pharm Design 2003; 9(15): 1177-89.
123. Walder K, Segal D, Jowett J, Blangero J, Collier GR. Obesity and diabetes gene discovery approaches. Curr Pharm Design 2003; 9(17): 1357-72.